What You Should Know
The Launch: FDB (First Databank) has announced the general availability of FDB MedProof MCP, the healthcare industry's first Model Context Protocol (MCP) server purpose-built for AI medication decision support.The Protocol: MCP is an emerging, open-source standard that defines how AI agents and Large Language Models (LLMs) interact with external knowledge bases. By creating an MCP server, FDB allows health-tech developers to plug generative AI directly into FDB's
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
The Role of Ethical Oversight and Algorithmic Bias in Automated Pharmacovigilance
Pharmacovigilance is changing quietly but fundamentally. You can feel it in the way adverse event reports move faster through systems, in how signals surface earlier, and in how dashboards now carry insights that once took weeks of manual review. Machine learning, natural language processing, and automation have become trusted partners in drug safety operations, handling volumes of data no human team could reasonably manage alone. Yet as these systems take on more responsibility, the role of
Read More
Insilico Medicine and Eli Lilly Form $2.75B AI Drug Discovery Collaboration
Insilico Medicine and Eli Lilly Announce $2.75B AI Drug Discovery Collaboration
- Drug Discovery Collaboration: Insilico Medicine, an AI-native clinical-stage biotech, has signed a massive drug discovery collaboration with pharma giant Eli Lilly.
- The Financials: The deal is structured with a highly lucrative $115M upfront payment to Insilico. With development, regulatory, and commercial milestones, the total deal value could reach $2.75 billion, plus tiered royalties on future
Read More
ImmuneBridge Secures $7.7M to Open Cell Therapy Manufacturing Platform to Biotech Partners
What You Should Know
The Funding & The Pivot: ImmuneBridge has secured a $7.7M second seed round (bringing its total seed funding to nearly $20M) led by NFX, with participation from One Way Ventures, M Ventures, Insight Partners, LongGame Ventures, T.Rx Capital, Healthspan Capital, Sand Hill Angels, and two independent investors. Crucially, the company is using this capital to make its proprietary cell therapy screening and manufacturing platform available to external co-development
Read More
LinusBio Expands Its Laser-Powered Hair Test to Help Rule Out Autism in Older Children
What You Should Know
The Expansion: LinusBio has expanded the availability of its ClearStrand-ASD test to children up to age 10. Previously, the test was only validated for children under 48 months.The Technology: ClearStrand-ASD is a first-of-its-kind biochemical screening test. It requires only a single, noninvasive strand of hair, which can be collected from children as young as one month old.How It Works: In a CLIA-certified laboratory, proprietary robotics and lasers analyze hundreds of
Read More
NVIDIA and Persistent Systems Partner to Bring ‘Agentic AI’ to Drug Discovery
What You Should Know
The Partnership: Persistent Systems, a global digital engineering firm, is collaborating with NVIDIA to deploy AI-powered solutions specifically for the Healthcare and Life Sciences (HLS) sector.The Goal: The collaboration aims to move BioPharma companies out of the "AI experimentation" phase and into real-world, production-grade deployments for computational drug discovery and research.The Tech Stack: Persistent is utilizing the full-stack NVIDIA AI platform, including
Read More
HIMSS26: Verily and Samsung Partner to Integrate Galaxy Watch 8 into Precision Health Platform
What You Should Know
The Partnership: Verily Life Sciences and Samsung Electronics America are collaborating to integrate the Samsung Galaxy Watch 8 directly into Verily’s precision health platform, Pre.The Clinical Goal: The joint solution is designed to accelerate research for life sciences and government customers by allowing them to run real-world studies using continuous, consumer-grade wearable data.The Hardware: The Galaxy Watch 8 acts as a robust clinical tool, bringing FDA-cleared
Read More
Why Pharma Must Adopt “Decision Engines” for Medical Engagement
Pharma medical affairs teams have spent the last decade investing heavily in digital transformation. Virtual advisory boards, omnichannel platforms, CRM systems, and analytics dashboards are now standard. Yet despite this progress, many medical engagement strategies still appear static. Plans are often locked in annually, channels are treated as separate silos, and success is measured by activity rather than relevance.
The disconnect is not a lack of data or tools. It is that engagement
Read More
Havas Health and BrightInsight Form Global Digital Health Partnership for Biopharma
What You Should Know
The Alliance: Havas Health has announced an exclusive, strategic partnership with BrightInsight, designating the firm as its single global agency partner for digital persistence and adherence solutions.The Core Problem: The pharmaceutical industry loses an estimated $500 billion annually because patients fail to adhere to or persist with their prescribed therapies.The Technology: BrightInsight brings a pre-vetted, regulatory-compliant digital health platform (powering
Read More
Lessons from COVID-19: How Agile Governance is Transforming Pharmaceutical Launch Readiness
The COVID-19 pandemic forced the pharmaceutical industry to do what once seemed impossible: compress launch cycles that traditionally stretched over a decade into mere months.
The urgency of the crisis redefined what “readiness” meant, with organizations working across functions, geographies, and regulators at a pace previously unthinkable. While the world has shifted into a post-pandemic reality, the lessons learned from this period of radical acceleration remain invaluable. The
Read More
